581065-95-4

Usage

Uses

Used in Pharmaceutical Industry:
H2N-PEG4-tBu is used as a linker-cytotoxin conjugate for the development of antibody-cytotoxin and antibody-drug conjugates. This application takes advantage of the molecule's reactivity with various functional groups, allowing for the creation of targeted therapies that can deliver cytotoxic agents specifically to cancer cells, minimizing damage to healthy cells.
Used in Drug Delivery Systems:
In the field of drug delivery, H2N-PEG4-tBu is utilized as a component in the design and synthesis of novel drug delivery systems. The hydrophilic PEG spacer and reactive amino group enable the conjugation of drugs or imaging agents to the carrier, improving the solubility, stability, and targeted delivery of therapeutic agents.
Used in Bioconjugation:
H2N-PEG4-tBu is also used as a bioconjugation agent, facilitating the attachment of biologically active molecules, such as peptides, proteins, or nucleic acids, to various surfaces or carriers. The t-butyl protected carboxyl group allows for controlled deprotection and subsequent conjugation under mild conditions, preserving the integrity of the biomolecule.
Used in Diagnostics:
In the diagnostics industry, H2N-PEG4-tBu can be employed as a component in the development of imaging agents or biosensors. The hydrophilic PEG spacer and reactive amino group can be used to attach contrast agents or signaling moieties to biomolecules, enhancing their detection and imaging capabilities in various diagnostic applications.

Upstream product

• 581066-04-8 tert-butyl 1-azido-3,6,9,12-tetraoxapentadecan-15-oate 
• 870487-48-2 tert-butyl 1-(methanesulfonyloxy)-3,6,9,12-tetraoxapentadecan-15-oate 
• 86770-67-4 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethanol 
• 77544-60-6 p-toluenesulfonic acid 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl ester 
• 1663-39-4 tert-Butyl acrylate 
• 112-60-7 Tetraethylene glycol 
• 581065-94-3 tert-butyl 3-[2-(2-{2-[2-(toluene-4-sulfonyloxy)-ethoxy]ethoxy}ethoxy)ethoxy]propionate 
• 518044-32-1 tert-butyl 3-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)propanoate 

Downstream Products

• 960215-56-9 1-{1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl}-2-oxo-6,9,12,15-tetraoxa-3-azaoctadecan-18-oic acid 
• 870487-58-4 C₂₅H₄₂N₂O₇S₂ 
• 1415329-56-4 C₂HF₃O₂*C₅₅H₉₆N₆O₁₃ 
• 1426164-52-4 MAL-Lys(MAL)-dPEG₄-acid 
• 1426164-53-5 bis-maleimide-lysine-PEG₄-TFP 
• 1426164-58-0 MAL-dPEG₂-Lys(MAL-dPEG₂)-dPEG₄-TFP 
• 1426164-49-9 tert-butyl (S)-9-(((benzyloxy)carbonyl)amino)-3,10-dioxo-1-phenyl-2,14,17,20,23-pentaoxa-4,11-diazahexacosan-26-oate 
• 1456794-49-2 C₄₀H₆₈N₆O₂₀P₂ 
• 663921-15-1 3-[2-(2-{2-[2-(2-aminoethoxy)ethoxy]ethoxy}ethoxy)ethoxy]propanoic acid 

Relevant academic research and scientific papers

Optimization of IEDDA bioorthogonal system: Efficient process to improve trans-cyclooctene/tetrazine interaction

The antibody pretargeting approach for radioimmunotherapy (RIT) using inverse electron demand Diels-Alder cycloaddition (IEDDA) constitutes an emerging theranostic approach for solid cancers. However, IEDDA pretargeting has not reached clinical trial. The major limitation of the IEDDA strategy depends largely on trans-cyclooctene (TCO) stability. Indeed, TCO may isomerize into the more stable but unreactive cis-cyclooctene (CCO), leading to a drastic decrease of IEDDA efficiency. We have thus developed both efficient and reproducible synthetic pathways and analytical follow up for (PEGylated) TCO derivatives, providing high TCO isomeric purity for antibody modification. We have set up an original process to limit the isomerization of TCO to CCO before the mAbs’ functionalization to allow high TCO/tetrazine cycloaddition.

STEROIDS AND PROTEIN-CONJUGATES THEREOF

Described herein protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.

Preparation method of amino polyethylene glycol propionic acid

The invention relates to the field of organic synthesis, in particular to a preparation method of amino polyethylene glycol propionic acid. The preparation method comprises the steps that catalytic hydrogenation is carried out on dibenzyl amino polyethylene glycol tert-butyl propionate shown in formula I-2 to obtain amino polyethylene glycol tert-butyl propionate shown in formula I-3; (2) the amino polyethylene glycol tert-butyl propionate shown in formula I-3 is hydrolyzed under the acidic condition to obtain amino polyethylene glycol propionic acid shown in formula I. The preparation methodof the amino polyethylene glycol propionic acid has the advantages that the defects in the prior art that the yield is low, the dangerousness is high, and the enlargement of production is difficult are overcome, the reaction conditions are mild, the operation is simple, an intermediate does not to be purified, the next reaction can be directly carried out, the whole yield reaches up to 87-92%, thepurity of end products reaches up to 97-99.5%, and a safe and efficient synthetic route is provided for the preparation of amino polyethylene glycol propionic acid.

Expedient synthesis of trifunctional oligoethyleneglycol-amine linkers and their use in the preparation of PEG-based branched platforms

We designed a convergent synthesis pathway that provides access to trifunctional oligoethyleneglycol-amine (OEG-amine) linkers. By applying the reductive coupling of a primary azide to bifunctional OEG-azide precursors, the corresponding symmetrical dialkylamine bearing two homo-functional end chain groups and a central nitrogen was obtained. These building blocks bear minimal structural perturbation compared to the native OEG backbone which makes them attractive for biomedical applications. The NMR investigations of the mechanism process reveal the formation of nitrile and imine intermediates which can react with the reduced free amine form. Additionally, these trifunctional OEG-amine linkers were employed in a coupling reaction to afford branched multifunctional PEG dendrons which are molecularly defined. These discrete PEG-based dendrons (n = 16, 18 and 36) could be useful for numerous applications where multivalency is required.

OPTIMIZED TRANSGLUTAMINASE SITE-SPECIFIC ANTIBODY CONJUGATION

Provided herein are methods and compositions for site-specific conjugation of antibodies.

A-amido glycol propionic acid preparation method (by machine translation)

The invention discloses a-amido glycol propionic acid (NH2 - PEGn - CH2 CH2 C00H, n=1 - 24) of the preparation method, the preparation method in order to mono-disperse small molecular double-hydroxy polyethylene

A new route for the synthesis of 1-amino-3,6,9,12-tetraoxapentadecan-15-oic acid

1-Amino-3,6,9,12-tetraoxapentadecan-15-oic acid 8 was synthesised from tetraethylene glycol through a 7 step sequence including esterification, mesylation, azide substitution with subsequent reduction followed by hydrolysis. The structure of product 8 was

ANTI-CD70 ANTIBODY DRUG CONJUGATES

This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES

This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.

COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES

Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.